XRAY Medical Devices · Dental · Turnaround · Medical devices · Thesis updated July 2, 2026

A dental turnaround with a long wait

XRAY is a dental products company trying to restart growth after weak equipment and implant demand.
Full-year 2025 net sales were $3.68 billion, down 4.3% on a constant currency basis.
Management says the Return-to-Growth plan is a 24-month plan, with larger benefits pushed to late 2026 and 2027.
The company cut the dividend and started a $120 million restructuring program to fund the turnaround.
The main investor question is whether new U.S. distributors and cost savings can offset weak volumes, tariffs, and Byte uncertainty.

01 Running thesis

A plan, not proof yet

DENTSPLY SIRONA is in the early part of a hard reset. Q1 2026 did not show the full benefit of the new plan yet. CEO Dan Scavilla said the company is where it expected to be at this stage, and management kept full-year guidance in place.

The bull case is patience. The company has a 24-month Return-to-Growth plan, a $120 million savings target, and four new U.S. distributor agreements signed in 2026. If those moves stop share loss in the U.S. and costs fall as planned, 2027 could show much better profit leverage.

The bear case is still the near-term base case. Sales and margins are starting from a weak place. Management itself says larger benefits should come in late 2026 and 2027, so investors must wait while execution risk stays high.

May 2026→Q1 2026 confirmed the Return-to-Growth plan is still early. Management kept guidance and said larger benefits should come late in 2026 and into 2027.

Feb 2026▼The company issued weak 2026 guidance, cut the dividend, and launched a $120 million restructuring plan. Another $144 million impairment charge showed more pressure in key segments.

Nov 2025▼Q3 2025 brought a major reset under the new CEO. U.S. sales were weak, EPS guidance was cut, and the CFO departure added leadership risk.

Aug 2025▼Q2 2025 showed deeper U.S. weakness and a $214 million impairment charge. The estimated annual tariff headwind rose to $80 million.

May 2025→Q1 2025 beat low expectations but still pointed to a shrinking year. U.S. sales were weak, and tariffs became a clearer cost risk.

Feb 2025▼2025 guidance called for another year of organic sales decline and lower adjusted EPS than prior targets. Byte was confirmed as a major drag.

Nov 2024▼The voluntary suspension of Byte sales created regulatory and strategic uncertainty. Management also cut 2024 guidance and cast doubt on its 2026 EPS target.

Jul 2024▼The initial view framed XRAY as a risky restructuring story. Connected Technology Solutions fell sharply, and the company moved to change its Patterson equipment distribution agreement.

02 Business model

Selling through dentists and dealers

XRAY makes products that dentists, orthodontists, oral surgeons, and some non-dental health providers use. It sells through its own sales force and through third-party distributors around the world.

The model works best when dentists are buying big equipment, like scanners and CAD/CAM systems, and when consumables keep moving through offices. It breaks when dentists delay large purchases or when distributors carry too much inventory.

Management is changing the U.S. go-to-market model. It is re-engaging dealer partners such as Patterson and Benco, adding new distributors, and shifting more capital equipment to a drop-ship model. That means XRAY tries to create real demand first, then ships product, instead of pushing units into dealer stock.

The dividend was eliminated after a strategic review. Management says the cash will go to debt retirement and share repurchases, while the restructuring program funds the Return-to-Growth plan.

03 Product portfolio

Four businesses, different problems

Option

Connected Technology Solutions

This includes CEREC, Primescan, imaging equipment, and treatment centers. It can be a powerful growth driver when dentists spend on technology, but demand for capital equipment is still soft.

Cash cow

Essential Dental Solutions

This is the consumables business for root canals, restorations, and preventive care. It is less exciting than scanners, but it is the largest 2025 segment by sales.

Option

Orthodontic and Implant Solutions

This segment includes SureSmile clear aligners and premium and value implants. Implants are under pressure, and management still needs to show when the core implant business can stabilize.

Option

Byte

Byte is the direct-to-consumer aligner brand. Sales, marketing, and shipments have been voluntarily suspended since late October 2024 while the company reviews regulatory needs and strategic options.

Growth engine

Wellspect HealthCare

Wellspect is the non-dental health products segment. Management has talked about long-term M&A interest here, including deals that could drive faster growth.

04 Business segments

2025 sales mix

Connected Technology Solutions28%declining

Essential Dental Solutions40%modest

Orthodontic and Implant Solutions23%declining

Wellspect HealthCare9%modest

The mix uses full-year 2025 net sales by segment: $3.68 billion in total. Essential Dental Solutions is the largest piece, while the main impairment pressure has been in Connected Technology Solutions and Orthodontic and Implant Solutions.

05 Risk factors

What could break the turnaround

U.S. distribution fails to move share

High impact · Medium odds

XRAY has signed four new U.S. distributor agreements in 2026. That is good only if it leads to real orders, not just more coverage on paper. The company needs U.S. sales to stabilize after a weak 2025.

We watchLook for Q3 and Q4 2026 commentary that U.S. sales have a plus sign or that market share has stopped falling.

Implants keep shrinking

High impact · High odds

The core implant business has been declining at a high-single-digit rate. This matters because implants sit in a key segment that has already taken large impairment charges. If the category stays weak, the turnaround may take longer than planned.

We watchTrack management comments on implant volume, pricing, and the timing of stabilization.

Savings arrive too late

High impact · Medium odds

The restructuring plan targets about $120 million of annual savings. Management says benefits build through 2026 and become more meaningful in the second half. A delay would leave XRAY with weak sales and higher investment spending at the same time.

We watchWatch second-half 2026 gross margin and operating margin for a clear turn.

Byte stays a drag

Medium impact · Medium odds

Byte sales, marketing, and shipments remain voluntarily suspended while XRAY reviews regulatory requirements and strategic options. The business already hurt sales growth. A costly fix or shutdown could add more distraction.

We watchWatch for an FDA-related update, a restart plan, a sale, or a formal discontinuation decision.

Cash has too many jobs

Medium impact · Medium odds

The company eliminated the dividend and said cash would be used for debt retirement and share repurchases. It also needs to fund the turnaround. If free cash flow disappoints, management may have to choose between balance sheet repair, buybacks, and investment.

We watchTrack 2026 free cash flow, net debt, and any change in buyback language.

06 Quick answers

In one breath

Is DENTSPLY SIRONA a dental equipment company?

Yes, but it is broader than equipment. It sells dental technology, implants, orthodontic products, dental consumables, and Wellspect health products.

Why did DENTSPLY SIRONA cut its dividend?

Management said the dividend was eliminated after a strategic review. The cash is being redirected toward debt retirement and share repurchases while the company funds its Return-to-Growth plan.

When could the turnaround show up in results?

Management described the plan as a 24-month plan. The company expects cost benefits to build through 2026, with more meaningful improvement late in 2026 and into 2027.